1
|
Chen Y, Jiang M, Chen X. Therapeutic potential of TNFR2 agonists: a mechanistic perspective. Front Immunol 2023; 14:1209188. [PMID: 37662935 PMCID: PMC10469862 DOI: 10.3389/fimmu.2023.1209188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Accepted: 07/31/2023] [Indexed: 09/05/2023] Open
Abstract
TNFR2 agonists have been investigated as potential therapies for inflammatory diseases due to their ability to activate and expand immunosuppressive CD4+Foxp3+ Treg cells and myeloid-derived suppressor cells (MDSCs). Despite TNFR2 being predominantly expressed in Treg cells at high levels, activated effector T cells also exhibit a certain degree of TNFR2 expression. Consequently, the role of TNFR2 signaling in coordinating immune or inflammatory responses under different pathological conditions is complex. In this review article, we analyze possible factors that may determine the therapeutic outcomes of TNFR2 agonism, including the levels of TNFR2 expression on different cell types, the biological properties of TNFR2 agonists, and disease status. Based on recent progress in the understanding of TNFR2 biology and the study of TNFR2 agonistic agents, we discuss the future direction of developing TNFR2 agonists as a therapeutic agents.
Collapse
Affiliation(s)
- Yibo Chen
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, Macau SAR, China
| | - Mengmeng Jiang
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, Macau SAR, China
| | - Xin Chen
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, Macau SAR, China
- Ministry of Education (MoE) Frontiers Science Center for Precision Oncology, University of Macau, Macau, Macau SAR, China
- Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Macau, Macau, Macau SAR, China
- Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, Macau, Macau SAR, China
| |
Collapse
|
4
|
Saeki Y, Okita Y, Igashira-Oguro E, Udagawa C, Murata A, Tanaka T, Mukai J, Miyazawa K, Hoshida Y, Ohshima S. Modulation of TNFR 1-triggered two opposing signals for inflammation and apoptosis via RIPK 1 disruption by geldanamycin in rheumatoid arthritis. Clin Rheumatol 2021; 40:2395-2405. [PMID: 33415454 DOI: 10.1007/s10067-021-05579-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2020] [Revised: 12/19/2020] [Accepted: 01/01/2021] [Indexed: 12/19/2022]
Abstract
OBJECTIVES To evaluate the ability of geldanamycin to modulate two opposing TNFα/TNFR1-triggered signals for inflammation and cell death. METHODS The effects of geldanamycin on TNFα-induced proinflammatory cytokine production, apoptosis, NF-κB activation, caspase activation, and necroptosis in a human rheumatoid synovial cell line (MH7A) were evaluated via ELISA/qPCR, flow cytometry, dual-luciferase reporter assay, and western blotting assay, respectively. In addition, therapeutic effects on murine collagen-induced arthritis (CIA) were also evaluated. RESULTS Geldanamycin disrupted RIPK1 in MH7A, thereby inhibiting TNFα-induced proinflammatory cytokine production and enhancing apoptosis. TNFα-induced NF-κB and MLKL activation was inhibited, whereas caspase 8 activation was enhanced. Recombinant RIPK1 restored the geldanamycin-mediated inhibition of TNFα-induced NF-κB activation. In addition, GM showed more clinical effectiveness than a conventional biologic TNF inhibitor, etanercept, in murine CIA and significantly attenuated synovial hyperplasia, a histopathological hallmark of RA. CONCLUSIONS GM disrupts RIPK1 and selectively inhibits the TNFR1-triggered NF-κB activation signaling pathway, while enhancing the apoptosis signaling pathway upon TNFα stimulation, thereby redressing the balance between these two opposing signals in a human rheumatoid synovial cell line. Therapeutic targeting RIPK1 may be a novel concept which involves TNF inhibitor acting as a TNFR1-signal modulator and have great potential for a more fundamental, effective, and safer TNF inhibitor. Key Points • Geldanamycin (GM) disrupts RIPK1 and selectively inhibits the TNFR1-triggered NF-κB activation signaling pathway while enhancing the apoptosis signaling pathway upon TNFα stimulation, thereby redressing the balance between these two opposing signals in a human rheumatoid synovial cell line, MH7A. • GM showed more clinical effectiveness than a conventional biologic TNF-inhibitor, etanercept, in murine collagen-induced arthritis (CIA), and significantly attenuated synovial hyperplasia, a histopathological hallmark of RA. • Therapeutic targeting RIPK1 may be a novel concept which involves TNF inhibitor acting as a TNFR1-signal modulator and have great potential for a more fundamental, effective, and safer TNF-inhibitor.
Collapse
Affiliation(s)
- Yukihiko Saeki
- Rheumatology & Allergology, NHO Osaka Minami Medical Center, Kidohigashi-machi, Kawachinagano, Osaka, 586-8521, Japan. .,Department of Clinical Research, NHO Osaka Minami Medical Center, 2-1 Kidohigashi-machi, Kawachinagano, Osaka, 586-8521, Japan.
| | - Yasutaka Okita
- Rheumatology & Allergology, NHO Osaka Minami Medical Center, Kidohigashi-machi, Kawachinagano, Osaka, 586-8521, Japan.,Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamada-oka, Suita, Osaka, 565-0871, Japan
| | - Eri Igashira-Oguro
- Rheumatology & Allergology, NHO Osaka Minami Medical Center, Kidohigashi-machi, Kawachinagano, Osaka, 586-8521, Japan.,Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamada-oka, Suita, Osaka, 565-0871, Japan
| | - Chikako Udagawa
- Department of Clinical Research, NHO Osaka Minami Medical Center, 2-1 Kidohigashi-machi, Kawachinagano, Osaka, 586-8521, Japan.,Molecular Chemistry, Faculty of Pharmacology, Osaka Ohtani University, Nishikiori-kita, Tondabayashi, Osaka, 584-8540, Japan
| | - Atsuko Murata
- Department of Clinical Research, NHO Osaka Minami Medical Center, 2-1 Kidohigashi-machi, Kawachinagano, Osaka, 586-8521, Japan
| | - Takashi Tanaka
- Molecular Chemistry, Faculty of Pharmacology, Osaka Ohtani University, Nishikiori-kita, Tondabayashi, Osaka, 584-8540, Japan
| | - Jyunji Mukai
- Department of Pharmacy, Izumi-City General Hospital, Wake-Cho, Izumi City, Osaka, 594-0072, Japan
| | - Keiji Miyazawa
- KISSEI Pharmaceutical CO., L.T.D, Yoshino, Matsumoto City, Nagano Prefecture, 399-8710, Japan
| | - Yoshihiko Hoshida
- Pathology, NHO Osaka Minami Medical Center, Kidohigashi-machi, Kawachinagano, Osaka, 586-8521, Japan
| | - Shiro Ohshima
- Rheumatology & Allergology, NHO Osaka Minami Medical Center, Kidohigashi-machi, Kawachinagano, Osaka, 586-8521, Japan.,Department of Clinical Research, NHO Osaka Minami Medical Center, 2-1 Kidohigashi-machi, Kawachinagano, Osaka, 586-8521, Japan
| |
Collapse
|
5
|
Pegoretti V, Baron W, Laman JD, Eisel ULM. Selective Modulation of TNF-TNFRs Signaling: Insights for Multiple Sclerosis Treatment. Front Immunol 2018; 9:925. [PMID: 29760711 PMCID: PMC5936749 DOI: 10.3389/fimmu.2018.00925] [Citation(s) in RCA: 70] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2017] [Accepted: 04/13/2018] [Indexed: 12/26/2022] Open
Abstract
Autoimmunity develops when self-tolerance mechanisms are failing to protect healthy tissue. A sustained reaction to self is generated, which includes the generation of effector cells and molecules that destroy tissues. A way to restore this intrinsic tolerance is through immune modulation that aims at refurbishing this immunologically naïve or unresponsive state, thereby decreasing the aberrant immune reaction taking place. One major cytokine has been shown to play a pivotal role in several autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS): tumor necrosis factor alpha (TNFα) modulates the induction and maintenance of an inflammatory process and it comes in two variants, soluble TNF (solTNF) and transmembrane bound TNF (tmTNF). tmTNF signals via TNFR1 and TNFR2, whereas solTNF signals mainly via TNFR1. TNFR1 is widely expressed and promotes mainly inflammation and apoptosis. Conversely, TNFR2 is restricted mainly to immune and endothelial cells and it is known to activate the pro-survival PI3K-Akt/PKB signaling pathway and to sustain regulatory T cells function. Anti-TNFα therapies are successfully used to treat diseases such as RA, colitis, and psoriasis. However, clinical studies with a non-selective inhibitor of TNFα in MS patients had to be halted due to exacerbation of clinical symptoms. One possible explanation for this failure is the non-selectivity of the treatment, which avoids TNFR2 stimulation and its immune and tissue protective properties. Thus, a receptor-selective modulation of TNFα signal pathways provides a novel therapeutic concept that might lead to new insights in MS pathology with major implications for its effective treatment.
Collapse
Affiliation(s)
- Valentina Pegoretti
- Department of Molecular Neurobiology (GELIFES), University of Groningen, Groningen, Netherlands
| | - Wia Baron
- Department of Cell Biology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands
| | - Jon D Laman
- Department of Neuroscience, University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands
| | - Ulrich L M Eisel
- Department of Molecular Neurobiology (GELIFES), University of Groningen, Groningen, Netherlands
| |
Collapse
|
6
|
Fischer CR, Mikami M, Minematsu H, Nizami S, Lee HG, Stamer D, Patel N, Soung DY, Back JH, Song L, Drissi H, Lee FY. Calreticulin inhibits inflammation-induced osteoclastogenesis and bone resorption. J Orthop Res 2017; 35:2658-2666. [PMID: 28460421 PMCID: PMC8996436 DOI: 10.1002/jor.23587] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2016] [Accepted: 04/07/2017] [Indexed: 02/04/2023]
Abstract
Osteoclasts play key roles in bone remodeling and pathologic osteolytic disorders such as inflammation, infection, bone implant loosening, rheumatoid arthritis, metastatic bone cancers, and pathological fractures. Osteoclasts are formed by the fusion of monocytes in response to receptor activators of NF-κB-ligand (RANKL) and macrophage colony stimulating factor 1 (M-CSF). Calreticulin (CRT), a commonly known intracellular protein as a calcium-binding chaperone, has an unexpectedly robust anti-osteoclastogenic effect when its recombinant form is applied to osteoclast precursors in vitro or at the site of bone inflammation externally in vivo. Externally applied Calreticulin was internalized inside the cells. It inhibited key pro-osteoclastogenic transcription factors such as c-Fos and nuclear factor of activated T cells, cytoplasmic 1 (NFATc1)-in osteoclast precursor cells that were treated with RANKL in vitro. Recombinant human Calreticulin (rhCRT) inhibited lipopolysaccharide (LPS)-induced inflammatory osteoclastogenesis in the mouse calvarial bone in vivo. Cathepsin K molecular imaging verified decreased Cathepsin K activity when rhCalreticulin was applied at the site of LPS application in vivo. Recombinant forms of intracellular proteins or their derivatives may act as novel extracellular therapeutic agents. We anticipate our findings to be a starting point in unraveling hidden extracellular functions of other intracellular proteins in different cell types of many organs for new therapeutic opportunities. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 35:2658-2666, 2017.
Collapse
Affiliation(s)
- Charla R. Fischer
- Robert Carroll and Jane Chace Carroll Laboratories, College of Surgeons and Physicians of Columbia University, 650 W. 168th Street, BB14-1412, New York, NY 10032
| | - Maya Mikami
- Robert Carroll and Jane Chace Carroll Laboratories, College of Surgeons and Physicians of Columbia University, 650 W. 168th Street, BB14-1412, New York, NY 10032
| | - Hiroshi Minematsu
- Robert Carroll and Jane Chace Carroll Laboratories, College of Surgeons and Physicians of Columbia University, 650 W. 168th Street, BB14-1412, New York, NY 10032
| | - Saqib Nizami
- Robert Carroll and Jane Chace Carroll Laboratories, College of Surgeons and Physicians of Columbia University, 650 W. 168th Street, BB14-1412, New York, NY 10032
| | - Heon Goo Lee
- Robert Carroll and Jane Chace Carroll Laboratories, College of Surgeons and Physicians of Columbia University, 650 W. 168th Street, BB14-1412, New York, NY 10032
| | - Danielle Stamer
- Department of Orthopaedic Surgery and Rehabilitation, Center for Musculoskeletal Care, Yale University School of Medicine, 47 College Street, New Haven, New York
| | - Neel Patel
- Department of Orthopaedic Surgery and Rehabilitation, Center for Musculoskeletal Care, Yale University School of Medicine, 47 College Street, New Haven, New York
| | - Do Yu Soung
- Robert Carroll and Jane Chace Carroll Laboratories, College of Surgeons and Physicians of Columbia University, 650 W. 168th Street, BB14-1412, New York, NY 10032
| | - Jung-ho Back
- Department of Orthopaedic Surgery and Rehabilitation, Center for Musculoskeletal Care, Yale University School of Medicine, 47 College Street, New Haven, New York
| | - Lee Song
- Robert Carroll and Jane Chace Carroll Laboratories, College of Surgeons and Physicians of Columbia University, 650 W. 168th Street, BB14-1412, New York, NY 10032
| | - Hicham Drissi
- Department of Orthopedic Surgery, Emory School of Medicine, Atlanta, GA
| | - Francis Y. Lee
- Department of Orthopaedic Surgery and Rehabilitation, Center for Musculoskeletal Care, Yale University School of Medicine, 47 College Street, New Haven, New York
| |
Collapse
|